PLx Pharma Winddown Gestione

Gestione criteri di controllo 1/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Pat Lonergan

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	no data
Proprietà del CEO	n/a
Durata media del management	Nessun dato
Durata media del Consiglio di amministrazione	5.8yrs

Aggiornamenti recenti sulla gestione

Recent updates

PLx Pharma Non-GAAP EPS of -$0.52 misses by $0.02, revenue of $0.48M

Aug 12

Is PLx Pharma (NASDAQ:PLXP) In A Good Position To Deliver On Growth Plans?

May 10

Most Shareholders Will Probably Find That The CEO Compensation For PLx Pharma Inc. (NASDAQ:PLXP) Is Reasonable

Nov 03

We're Interested To See How PLx Pharma (NASDAQ:PLXP) Uses Its Cash Hoard To Grow

Sep 23

AMMINISTRATORE DELEGATO

Pat Lonergan (88 yo)

no data

Mandato

Mr. Patrick M. Lonergan, also known as Pat, co-founded Numark Laboratories Inc. in 1987 and has been its President since January 1989. Mr. Lonergan serves as Member of Chief Executive Officer Advisory Grou...

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Michael Valentino	Chairman	12.3yrs	US$393.75k	1.62% $ 0.5
Kirk Calhoun	Independent Director	8yrs	US$55.00k	0.0055% $ 0.002
Todd Rosengart	Member of Scientific Advisory Board	5.8yrs	Nessun dato	Nessun dato
Robert Casale	Independent Director	7.7yrs	US$75.50k	0.0089% $ 0.003
Gary Balkema	Independent Director	7.7yrs	US$50.00k	0.018% $ 0.005
P. Steg	Member of Scientific Advisory Board	5.8yrs	Nessun dato	Nessun dato
Deepak Bhatt	Member of Scientific Advisory Board	5.8yrs	Nessun dato	Nessun dato
Byron Cryer	Member of Scientific Advisory Board	5.8yrs	Nessun dato	Nessun dato
Jayne Prats	Member of Scientific Advisory Board	5.8yrs	Nessun dato	Nessun dato
Efthymios Deliargyris	Member of Scientific Advisory Board	3.5yrs	US$801.65k	Nessun dato
Dominick Angiolillo	Member of Scientific Advisory Board	5.8yrs	Nessun dato	Nessun dato
Carey Kimmelstiel	Member of Scientific Advisory Board	5.8yrs	Nessun dato	Nessun dato

5.8yrs

Durata media

66.5yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di PLXP.Q sono considerati esperti (durata media dell'incarico 5.8 anni).

PLx Pharma Winddown Gestione

Gestione criteri di controllo 1/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Plx Pharma Winddown Corp. Announces Executive Changes

PLx Pharma Inc. Announces Resignation of John W. Hadden II as Member of Board

PLx Pharma Inc., Annual General Meeting, Nov 08, 2022

Key Executive recently bought US$50k worth of stock

Key Executive recently bought US$50k worth of stock

Key Executive recently bought US$50k worth of stock

Recent updates

PLx Pharma Winddown Corp. Files Form 15

Plx Pharma Winddown Corp. Announces Executive Changes

PLx Pharma Receives Written Notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC

PLx Pharma Inc. Announces Resignation of John W. Hadden II as Member of Board

PLx Pharma Inc. to Report Q3, 2022 Results on Nov 11, 2022

PLx Pharma Receives Written Notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC Regarding Minimum Bid Price Requirement

PLx Pharma Inc., Annual General Meeting, Nov 08, 2022

PLx Pharma Non-GAAP EPS of -$0.52 misses by $0.02, revenue of $0.48M

PLx Pharma Inc. to Report Q2, 2022 Results on Aug 12, 2022

Consensus forecasts updated

Is PLx Pharma (NASDAQ:PLXP) In A Good Position To Deliver On Growth Plans?

Price target decreased to US$16.33

PLx Pharma Inc. to Report Q1, 2022 Results on May 13, 2022

Key Executive recently bought US$50k worth of stock

Key Executive recently bought US$50k worth of stock

Key Executive recently bought US$50k worth of stock

No longer forecast to breakeven

PLx Pharma Inc. to Report Q4, 2021 Results on Mar 11, 2022

Most Shareholders Will Probably Find That The CEO Compensation For PLx Pharma Inc. (NASDAQ:PLXP) Is Reasonable

We're Interested To See How PLx Pharma (NASDAQ:PLXP) Uses Its Cash Hoard To Grow

PLx Pharma: First Commercial Launch Makes It Attractive

Consensus forecasts updated

PLx Pharma Inc.’s VAZALORE to Launch in Nearly 8,000 CVS Stores this Month

Consensus revenue estimates fall to US$5.73m

Price target increased to US$21.50

PLx Pharma Inc.’s VAZALORE to Launch in over 8,000 Walgreens Stores Nationwide in August

Plx Pharma Inc.’s VAZALORE to Launch in over 4,500 Walmart Stores Nationwide in August

Executive Chairman recently bought US$100k worth of stock

PLx Pharma (NASDAQ:PLXP) Is In A Strong Position To Grow Its Business

Consensus forecasts updated

Consensus revenue estimates increase to US$6.80m

Earnings beat expectations

Executive Chairman recently bought US$200k worth of stock

PLx Pharma Inc. has completed a Follow-on Equity Offering in the amount of $63 million.

Have Insiders Been Buying PLx Pharma Inc. (NASDAQ:PLXP) Shares?

PLx Pharma Inc. has completed a Follow-on Equity Offering in the amount of $2.3 million.

PLx Pharma Receives FDA Approval of sNDAs for Both Vazalore 325 Mg and 81 Mg

New 90-day high: US$6.89

New 90-day high: US$6.50

PLx Pharma Inc. announced that it has received $18.008598 million in funding from White Rock Capital Management, L.P., Level One Partners LLC and other investors

PLx Pharma Inc. Submits Supplemental New Drug Applications for VAZALORE™ 325 mg and 81 mg to U.S. Food and Drug Administration

PLx Pharma Inc. announced that it expects to receive $18.008598 million in funding from White Rock Capital Management, L.P., Level One Partners LLC and other investors

PLx Pharma EPS misses by $0.10

Earnings miss expectations

New 90-day high: US$4.31

PLx Pharma Inc. to Report Q3, 2020 Results on Nov 13, 2020

New 90-day high - US$4.18

PLx Pharma Inc. to Report Q2, 2020 Results on Aug 14, 2020

PLx Pharma Inc.(NasdaqCM:PLXP) dropped from Russell Microcap Value Index

AMMINISTRATORE DELEGATO

Mandato

Membri del Consiglio di amministrazione

Durata media

Età media